SCHEMBL4253496

SCHEMBL4253496

CC(C)(C)OC(=O)/C=C(\Oc1ccc([N+](=O)[O-])cc1)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
BCL9 O00512 1/20 0.46
CTNNB1 P35222 1/20 0.46
ALDH1A1 P00352 5/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KMT2A Q03164 3/20 0.42
PKM P14618 1/20 0.42
MGLL Q99685 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
HGFAC Q04756 1/20 0.40
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
THRB P10828 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTR2A P28223 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4253501 1.00 GAA (0.48) GAABCL9CTNNB1ALDH1A1MAPT
SCHEMBL4256047 1.00 GAA (0.48) GAABCL9CTNNB1ALDH1A1MAPT
SCHEMBL4258062 0.85 MAPT (0.46) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL4251542 0.85 MAPT (0.46) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL4251537 0.85 MAPT (0.46) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL4251631 0.79 GAA (0.51) GAABCL9CTNNB1ALDH1A1MAPT
SCHEMBL4251629 0.79 GAA (0.51) GAABCL9CTNNB1ALDH1A1MAPT
SCHEMBL4254429 0.79 GAA (0.51) GAABCL9CTNNB1ALDH1A1MAPT
SCHEMBL1461897 0.78 ELANE (0.60) GAABCL9CTNNB1ALDH1A1MAPT
SCHEMBL4254520 0.78 ALDH1A1 (0.47) GAAALDH1A1MAPTKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2105432-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-2105431-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-1867626-A2 Process for producing chromone compound Sumitomo Chemical Company, Limited (JP) 2007-12-19 EP disclosed
US-20060217565-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-28 US disclosed
US-7094914-B2 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-22 US disclosed
US-20050085664-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LMITED (JP) 2005-04-21 US disclosed
EP-1479667-A1 PROCESS FOR PRODUCING CHROMONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085664-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL GAA 2812/4885BCL9 4330/4885CTNNB1 1544/4885
US-20060217565-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL GAA 2812/4885BCL9 4330/4885CTNNB1 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.